A 38-year-old woman with metastatic breast cancer is receiving 5-fluorouracil (5-FU) as part of her chemotherapy regimen. After the second cycle, she presents with severe hand and foot erythema, blistering, and desquamation. Her oncologist notes that she has a known deficiency in dihydropyrimidine dehydrogenase (DPD) activity. Which of the following best explains why this patient is at increased risk for severe 5-FU toxicity?

Explanation

## Dihydropyrimidine Dehydrogenase (DPD) Deficiency and 5-FU Toxicity ### 5-Fluorouracil Metabolism **Key Point:** 5-FU is a pyrimidine antimetabolite that requires careful metabolic balance. The majority of 5-FU (>80%) is catabolized by DPD to inactive metabolites; only a small fraction is converted to active metabolites. ### Normal 5-FU Metabolism Pathway ```mermaid flowchart TD A["5-Fluorouracil (5-FU)"]:::outcome --> B{"Metabolic fate?"}:::decision B -->|"~80-90% catabolism"| C["DPD converts 5-FU to DHFU"]:::action C --> D["Further degradation to inactive metabolites"]:::action B -->|"~10-20% activation"| E["Orotate phosphoribosyltransferase"]:::action E --> F["5-FdUMP (active metabolite)"]:::outcome F --> G["Inhibits thymidylate synthase"]:::action G --> H["Blocks dTMP synthesis"]:::outcome D --> I["Urinary excretion"]:::outcome ``` ### DPD Deficiency: Loss of Inactivation Pathway **High-Yield:** DPD deficiency is a **pharmacogenetic variant** that impairs the catabolism of 5-FU. Without functional DPD: 1. **Accumulation of active metabolites:** - 5-FU cannot be efficiently converted to DHFU (the first inactivation step) - Active metabolites (5-FdUMP, 5-FdUTP) accumulate to toxic levels - Prolonged exposure of tissues to active drug 2. **Consequence:** - Severe myelosuppression - Mucositis - **Hand-foot syndrome (palmoplantar erythrodysesthesia)** — characteristic of excessive 5-FU exposure - Potentially fatal toxicity if dose not adjusted ### Hand-Foot Syndrome (HFS) Pathophysiology **Clinical Pearl:** HFS is a dose-limiting toxicity of 5-FU characterized by: - Erythema, edema, and blistering of palms and soles - Results from accumulation of active 5-FU metabolites in highly perfused, rapidly dividing tissues - More common in patients with DPD deficiency or receiving high-dose 5-FU - Reversible upon dose reduction or discontinuation ### Pharmacogenetic Testing **Mnemonic:** **DPD-DEFICIENT = DANGEROUS DOSE** - Patients with DPD deficiency should receive **reduced 5-FU doses** (typically 25-50% of standard dose) - Genetic testing for DPD variants is increasingly recommended before 5-FU administration - Common DPD variants: DPYD*2A, DPYD*13, and others ### Comparison of Antimetabolite Toxicities and Metabolism | Drug | Activation | Inactivation | Dose-Limiting Toxicity | Pharmacogenetic Risk | |------|-----------|--------------|------------------------|----------------------| | 5-FU | Orotate PRT | DPD (80-90%) | Mucositis, HFS, myelosuppression | DPD deficiency (severe) | | Methotrexate | DHFR inhibitor | Hepatic metabolism | Myelosuppression, nephrotoxicity | MTHFR variants (minor) | | Cytarabine | Deoxycytidine kinase | Cytidine deaminase | Myelosuppression, mucositis | Cytidine deaminase (minor) | | Mercaptopurine | HGPRT | Xanthine oxidase | Myelosuppression, hepatotoxicity | TPMT deficiency (severe) | [cite:KD Tripathi 8e Ch 65; Harrison 21e Ch 102] ## Why the Other Options Are Wrong **Option 1 (Impaired activation):** DPD deficiency does NOT impair activation of 5-FU. Activation occurs via orotate phosphoribosyltransferase (a separate enzyme), which is unaffected by DPD deficiency. The problem is **loss of inactivation**, not loss of activation. This option reverses the mechanism. **Option 2 (Increased 5-FdUTP):** While 5-FdUTP does accumulate in DPD deficiency, the mechanism is NOT that DPD "increases" its conversion. Rather, DPD deficiency prevents the **catabolism** of 5-FU, allowing active metabolites to accumulate. The wording is mechanistically incorrect — DPD is a catabolic enzyme, not an activating enzyme. **Option 3 (Thymidine monophosphate synthesis):** This option confuses the mechanism. DPD deficiency does NOT directly prevent dTMP synthesis; rather, it allows excessive accumulation of 5-FdUMP, which **inhibits** thymidylate synthase and **blocks** dTMP synthesis. The mechanism is indirect (via excessive inhibition), not direct (via DPD loss).